NMDA receptor

Assets acting on this target.

Class
NMDA receptor antagonist

The N-methyl-D-aspartate (NMDA) receptor is a subtype of glutamate-gated ion channel found throughout the central nervous system. Glutamate is the principal excitatory neurotransmitter in the brain, and NMDA receptors, when activated, allow calcium and other ions to flow into neurons, a step central to synaptic plasticity, learning, and memory. Under pathological conditions, however, excessive or dysregulated NMDA receptor activity can drive excitotoxicity, contributing to neuronal injury, and it has also been implicated in mood disorders, chronic pain, and movement disorders. NMDA receptor antagonists reduce this ion flow, either by blocking the channel pore directly, by occupying the glutamate or glycine binding sites, or by acting at specific accessory subunits (such as GluN2B) that shape the receptor's location and function. Depending on the degree and selectivity of blockade, this can produce rapid changes in mood circuitry, dampen pain signaling, or reduce abnormal motor circuit activity. Because NMDA receptors are essential for normal cognition, antagonism carries an inherent trade-off between therapeutic benefit and effects such as dissociation, sedation, or memory disturbance. This mechanism underlies interest in treatment-resistant depression, neuropathic pain, and adjunctive management of movement disorders, among other areas of active investigation.

By indication

Related mechanisms

NMDA receptor drugs compared

11 drugs, stage by indication
11 drugs acting on NMDA receptor: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Amantadine ER (Gocovri/ADS-5102)GocovriAdamas Pharmaceuticals, Supernus Pharmaceuticalssmall moleculeApprovedApproved in Parkinson's Disease
EsketamineSpravatoJohnson & Johnsonsmall moleculeApprovedApproved in Major Depressive Disorder
ACP-211Acadia Pharmaceuticalssmall moleculePhase 2Phase 2 in Major Depressive Disorder
Arketamine (PRT042)Sichuan Purity Pharmaceutical Technologysmall moleculePhase 2Phase 2 in Major Depressive Disorder
AV-101VistaGen Therapeuticssmall moleculePhase 2Phase 2 in Major Depressive Disorder
BI 1569912Boehringer Ingelheimsmall moleculePhase 2Phase 2 in Major Depressive Disorder
BlixeprodilGilgamesh Pharmasmall moleculePhase 2Phase 2 in Major Depressive Disorder
Esketamine (CLE-100)Clexio Biosciencessmall moleculePhase 2Phase 2 in Major Depressive Disorder
ZelquistinelSyndeio Biosciencessmall moleculePhase 2Phase 2 in Major Depressive Disorder
ALA-3000Alar Pharmaceuticalssmall moleculePhase 1Phase 1 in Major Depressive Disorder
SP-101Synphatec (Shanghai) Biopharmaceuticalsmall moleculePhase 1Phase 1 in Major Depressive Disorder

← all mechanisms